Preserving eyesight

Latest News

  • EUROCONDOR Final General Assembly and EASDec 2016

    The EUROCONDOR project held its 6th and final General Assembly on Wednesday 22nd and Thursday 23rd of June 2016 at Citylabs facilities in Manchester, U.K. right before the beginning of the EASDec 2016 (annual meeting of the European Association for the Study of Diabetes Eye Complications).

  • World Diabetes Day (#WDD 2015) - November 14th

    As every year, November 14th was World Diabetes Day (WDD), the first and largest global awareness campaign on Diabetes. By that date, the EUROCONDOR project just completed its one-of-a-kind 2-year clinical trial, whose results will be available in March 2016! Follow the latest news on the project on this website and learn more about World Diabetes Day with our partner IDF-Europe!

  • EVER 2015 Congress - Nice, France, October 7th-10th

    This year's edition of EVER Congress hosted lectures from several partners of the EUROCONDOR Consortium, mostly in a session titled "Diabetic Retinopathy: a neurodegenerative disease", which addressed very specifically the innovative focus and rationale of our project.


    EUROCONDOR took part in World Sight Day, a global annual event to focus attention worldwide on vision impairment and blindness. This year's call for action was EYE CARE FOR ALL!, a priority of the project which aims at improving the lives of millions of people living with diabetes and Diabetic Retinopathy.

  • Partner IDF-Europe represents EUROCONDOR at the 51st Annual Congress of EASD

    [P]This year's edition of the EASD (European Association for the Study of Diabetes) congress was held in Stockholm, from September 14th to 18th 2015.

  • EUROCONDOR Annual Meeting, Turin, June 26th 2015

    This year, the EUROCONDOR partners held their 5th General Assembly in Turin. As a satellite of the EASDec 2015 congress, this Annual Meeting was held in the Aula Magna lecture room of the Cavallerizza Reale, an iconic architectural complex from the mid XVIIIth century. The lectures and presentations gave all partners a chance to review together the progress of the project and its 2-year one-of-a-kind Clinical Trial.

  • EUROCONDOR at 2015 BIO International Convention

    BCN Peptides, one of EUROCONDOR partners, attended the 2015 BIO International Convention. Celebrated in Philadelphia, from June 15th to 18th, it is the world's largest biotechnology gathering. Aside from giving visibility to the EUROCONDOR project, BCN Peptides explored partnership opportunities and potential outcomes for Somatostatin eyedrops..

  • Combating vision loss: an inside view of EUROCONDOR

    In an article recently published by the International Diabetes Federation Europe, Prof Scanlon and Elena Beltramo explain what the research project is all about.

  • Prof Simó shares views on diabetic retinopathy

    Prof Simó was a guest speaker on diabetic retinopathy at REDDSTAR's exploitation workshop on 21 October 2014. The project looks at how stromal cell therapy can be used to treat diabetes and prevent complications.

  • EUROCONDOR partners take stock of project's progress at 4th Annual Meeting

    Partners of the project met a few weeks ago to review the progress of the clinical trial which started early 2013, and to identify the next steps in the project.

  • REDDSTAR Project: Reducing diabetes complications using stem cells

    The REDDSTAR Project will examine if Stromal Stem Cells can safely control glycaemia and alleviate damage caused by six diabetes-related complications.

  • Visit the IDF Europe Newsroom for the latest news on European research on diabetes in Europe

    IDF Europe, partner of EUROCONDOR, has built an online platform to share the latest developments of research projects in the field of diabetes and chronic diseases.

  • AIBILI to present EUROCONDOR baseline data at 2014 ARVO annual meeting

    EUROCONDOR project partner AIBILI will present the project's baseline data in a poster presentation at the annual meeting of the Association for Research in Vision and Ophthalmology held from 4 to 8 May 2014 in Orlando, Florida.

  • Prof. Simó gives an update on EUROCONDOR at 2014 Euretina Winter Meeting

    EUROCONDOR Project Coordinator Prof. Simó from VHIR gave a presentation on the "Metabolic fingerprints of proliferative diabetic retinopathy"

  • EUROCONDOR project on EU research online portal

    EUROCONDOR is now part of the online portal, an EU initiative that aims to promote European research projects to the general public

  • EUROCONDOR clinical trial to begin in February 2013

    Clinical trial to test the safety and effectiveness of a new therapeutic treatment to combat diabetic retinopathy to start in several clinical centres across Europe.

  • EUROCONDOR in Parliament Magazine - November 2012

    Coinciding with World Diabetes Day, Dr. Rafael Simó presented the EUROCONDOR project to Parliament Magazine.



Diabetes mellitus is a chronic condition that arises when the pancreas does not produce any insulin, or not enough, or when the body cannot properly use the insulin it produces (known as insulin resistance). Insulin is a hormone produced by the pancreas that allows glucose to enter the body's cells and transforms it into energy needed for daily life. Failure to produce insulin, or of insulin to act properly, or both, leads to high blood glucose levels. This, in turn, is associated with long-term damage to the body and failure of various organs and tissues.

In 2012, 371 million people worldwide were living with diabetes. Estimates predict that this number will rise to 552 million by 2030 (IDF Diabetes Atlas, 5th edition Update, November 2012).

There are three main types of diabetes:

  • Type 1 diabetes occurs when the body's defence system attacks the insulin-producing cells in the pancreas. The body can no longer produce the insulin it needs. Type 1 diabetes can develop at any age, but it usually occurs in children or young adults. People with this form of diabetes need injections of insulin every day in order to control the levels of glucose in their blood.
  • Type 2 diabetes is the most common type of diabetes. Type 2 diabetes develops when the body does not produce enough insulin or when the body cannot properly use the insulin it produces. This leads to high levels of glucose in the blood. It usually occurs in adults, but is increasingly seen in children, adolescents and young adults. Much of type 2 diabetes can be prevented or delayed.
  • Gestational Diabetes Mellitus is first diagnosed during pregnancy. It generally develops when the body cannot produce enough insulin to meet the extra needs of pregnancy. Gestational diabetes can lead to serious pregnancy complications for mother and child and a life-time increased risk of type 2 diabetes.